Premium
Loss of MiR‐424‐3p, not miR‐424‐5p, confers chemoresistance through targeting YAP1 in non‐small cell lung cancer
Author(s) -
Zhang Meichun,
Zeng Jun,
Zhao Ziwen,
Liu Zhaohui
Publication year - 2017
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.22536
Subject(s) - yap1 , biology , cancer research , lung cancer , transfection , microrna , downregulation and upregulation , viability assay , cell , cell culture , oncology , gene , transcription factor , medicine , genetics
MiR‐424 has been discovered to be involved in the chemoresistance of lung cancer. However, the underlying mechanism by which miR‐424 played role in chemoresistance has been unknown. Here, in our study, to investigate the role of miR‐424 in non‐small cell lung cancer (NSCLC), we have detected the expression of miR‐424‐3p and ‐5p in NSCLC tissues and paired normal control. Moreover, to explore the role of miR‐424‐3p in NSCLC cells, miR‐424‐3p and ‐5p were both re‐expressed and knocked down using transient transfection with their respective mimics and inhibitors. Cell viability, migration, and invasion were evaluated using MTT, wound‐healing and Transwell assays, respectively. It was found that down‐regulation of miR‐424‐3p was pronouncedly associated with NSCLC progression and overall prognosis; and that both miR‐424‐3p and ‐5p were markedly capable of preventing the proliferation, migration, and invasion in NSCLC cells. Additionally, it is miR‐424‐3p but not miR‐424‐5p that enhances the chemo‐sensitivity of NSCLC cells through targeting YAP1. Mechanistically, YAP1 was identified as down‐stream target of miR‐424‐3p. Together, it was for the first time in our study found that it is loss of miR‐424‐3p not miR‐424‐5p that enables chemoresistance through targeting YAP1 in NSCLC, supporting that miR‐424‐3p could be used as therapeutic target in the curing of NSCLC with chemoresistance. © 2016 Wiley Periodicals, Inc.